




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2A




FIG. 2B









FIG. 3A

FIG. 3B

FIG. 3C





*p<0.05 vs PBS / IgG4P
&p<0.05 vs Semaglutide / IgG4P
#p<0.05 vs REGN1033 & REGN2477





FIG. 6A

Glucagon staining in pancreatic islets**FIG. 6B**

*p<0.05 vs PBS / IgG4P
&p<0.05 vs Semaglutide / IgG4P
#p<0.05 vs REGN1033 & REGN2477

Plasma measurements




FIG. 7A




FIG. 7B







FIG. 7C

*p<0.05 vs PBS / IgG4P
&p<0.05 vs Semaglutide / IgG4P
#p<0.05 vs REGN1033 & REGN2477






FIG. 8A




FIG. 8B




FIG. 9A





FIG. 9B

FIG. 10



- Vehicle
- Semaglutide 10µg/kg
- ▲ α-MSTN 50mg/kg + α-Activin A 50mg/kg
- ▽ Semaglutide 10µg/kg + α-MSTN 50mg/kg
- ◆ Semaglutide 10µg/kg + α-MSTN 50mg/kg + α-Activin A 50mg/kg




FIGURE 11A




FIGURE 11B




FIGURE 12A





FIGURE 12B



- Vehicle
- Semaglutide 10µg/kg
- ▲ α-MSTN 50mg/kg + α-Activin A 50mg/kg
- ▽ Semaglutide 10µg/kg + α-MSTN 50mg/kg
- ◆ Semaglutide 10µg/kg + α-MSTN 50mg/kg + α-Activin A 50mg/kg

Fasting Glucose

Veh	Sema	α-MSTN α-Activin A	α-MSTN Sema	α-MSTN α-Activin A Sema
-5%	-30.4%	-1.9%	-16.3%	-26%




FIGURE 13A






FIGURE 13B








FIGURE 14B




FIGURE 14C





FIGURE 14D








FIGURE 15A








FIGURE 16A





FIGURE 16B






FIGURE 17B




FIGURE 18

ActA, activin A; DXA, dual-energy X-ray absorptiometry; IV, intravenous; MRI, magnetic resonance imaging; MSTN, myostatin; Q2W, every 2 weeks; QW, every week. * $P < 0.5$, ** $P < 0.1$ vs. Placebo




FIGURE 19A

ActA, activin A; DXA, dual-energy X-ray absorptiometry; IV, intravenous; MRI, magnetic resonance imaging; MSTN, myostatin; Q2W, every 2 weeks; QW, every week. * $P < 0.5$, ** $P < 0.1$ vs. Placebo




FIGURE 19B

ActA, activin A; DXA, dual-energy X-ray absorptiometry; IV, intravenous; MRI, magnetic resonance imaging; MSTN, myostatin; Q2W, every 2 weeks; QW, every week. * $P < 0.5$, ** $P < 0.1$ vs. Placebo




FIGURE 19C






FIGURE 19D






FIG. 21A




FIG. 21B

- Vehicle
- Semaglutide
- △

α-MSTN + α-Activin A
- ▽

Semaglutide + α-MSTN
- ◇

Semaglutide + α-MSTN + α-Activin A




FIGURE 22A




FIGURE 22B





FIGURE 22C




FIGURE 22D





FIGURE 22E




FIGURE 22F




FIGURE 23